Ibutamoren MK-677 has been shown to sustain activation of GH–IGF-1 and to increase lean body mass with no change in total fat mass or visceral fat. It is under investigation as a potential treatment for reduced levels of these hormones. Human studies have shown ibutamoren to increase both muscle mass and bone mineral density, making it a promising potential therapy for the treatment of frailty in the elderly. Ibutamoren is in the pre-clinical stage of development for growth hormone deficiency.
*None of our products are intended for use in humans or animals. These products are intended for laboratory use by trained professional researchers only.